Zutectra Den europeiske union - norsk - EMA (European Medicines Agency)

zutectra

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera og immunglobuliner, - forebygging av hepatitt b-virus (hbv) re-infeksjon hos hbsag og hbv-dna-negative voksne pasienter minst en uke etter levertransplantasjon for hepatitt b-indusert leversvikt. hbv-dna-negativ status bør bekreftes i løpet av de siste 3 månedene før olt. pasienter bør være hbsag-negative før behandlingsstart. samtidig bruk av tilstrekkelig virostatic agenter bør betraktes som standard av hepatitt b re-infeksjon prophylaxis.

Human Albumin Biotest 200 g/ L Norge - norsk - Statens legemiddelverk

human albumin biotest 200 g/ l

biotest pharma gmbh - humanalbumin - infusjonsvæske, oppløsning - 200 g/ l

Hepatect 50 IE/ ml Norge - norsk - Statens legemiddelverk

hepatect 50 ie/ ml

biotest pharma gmbh - immunglobulin mot hepatitt b, humant - infusjonsvæske, oppløsning - 50 ie/ ml

Intratect 100 g/ L Norge - norsk - Statens legemiddelverk

intratect 100 g/ l

biotest pharma gmbh - immunglobulin, normalt (humant) - infusjonsvæske, oppløsning - 100 g/ l

Vihuma Den europeiske union - norsk - EMA (European Medicines Agency)

vihuma

octapharma ab - simoctocog alfa - hemofili a - antihemoragika - behandling og profylakse av blødning hos pasienter med hemofili a (medfødt faktor viii-mangel). vihuma kan brukes for alle aldersgrupper.

Lecigon Norge - norsk - Statens legemiddelverk

lecigon

lobsor pharmaceuticals ab - levodopa / karbidopamonohydrat / entakapon - intestinalgel - 20 mg/ ml / 5 mg/ ml / 20 mg/ ml

Duodopa 20 mg/ ml / 5 mg/ ml Norge - norsk - Statens legemiddelverk

duodopa 20 mg/ ml / 5 mg/ ml

abbvie as - levodopa / karbidopamonohydrat - intestinalgel - 20 mg/ ml / 5 mg/ ml

Sutent Den europeiske union - norsk - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Accord Den europeiske union - norsk - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Qinlock Den europeiske union - norsk - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.